Sarepta Shares Jump as FDA Official Departs; Jim Cramer Says It's Good News

Jim Cramer is watching Sarepta shares after an FDA official critical of the drug steps down.
Publish date:

TheStreet's Jim Cramer says the departure of a high ranking FDA official is good news for Sarepta Therapeutics  (SRPT) - Get Report . Dr. Ronald Farkas left the FDA for the private sector last week. Farkas was in charge of the FDA's clinical review team, which argued against the approval of Sarpeta's drug eteplirsen. Sarepta filed for approval of the drug over a year ago.